22-28699936-T-C
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 0P and 1B. BP4
The NM_007194.4(CHEK2):c.910A>G(p.Met304Val) variant causes a missense, splice region change. The variant allele was found at a frequency of 0.0000124 in 1,612,008 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_007194.4 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -1 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 151992Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.0000359 AC: 9AN: 250794Hom.: 0 AF XY: 0.0000443 AC XY: 6AN XY: 135522
GnomAD4 exome AF: 0.0000103 AC: 15AN: 1460016Hom.: 0 Cov.: 29 AF XY: 0.0000110 AC XY: 8AN XY: 726228
GnomAD4 genome AF: 0.0000329 AC: 5AN: 151992Hom.: 0 Cov.: 31 AF XY: 0.0000404 AC XY: 3AN XY: 74224
ClinVar
Submissions by phenotype
not provided Uncertain:3
- -
- -
Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 16794575, 33471991, 22419737, 19782031, 31206626, 28779002) -
Hereditary cancer-predisposing syndrome Uncertain:3
This missense variant replaces methionine with valine at codon 304 of the CHEK2 protein. Computational prediction suggests that this variant may not impact protein structure and function. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with breast and or ovarian cancer (PMID: 28779002, 31206626, 33471991). This variant has been identified in 9/250794 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
- -
The p.M304V variant (also known as c.910A>G), located in coding exon 8 of the CHEK2 gene, results from an A to G substitution at nucleotide position 910. The methionine at codon 304 is replaced by valine, an amino acid with highly similar properties. This alteration has been reported in at least one subject in a study of 13087 breast cancer cases and 5488 control individuals in the UK (Decker B et al. J. Med. Genet., 2017 11;54:732-741). This alteration was also identified in an individual diagnosed with breast and/or ovarian cancer (Weitzel JN et al. Cancer, 2019 08;125:2829-2836). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. -
Familial cancer of breast Uncertain:3
- -
This sequence change replaces methionine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 304 of the CHEK2 protein (p.Met304Val). This variant is present in population databases (rs769436449, gnomAD 0.02%). This missense change has been observed in individual(s) with breast cancer (PMID: 38061684). ClinVar contains an entry for this variant (Variation ID: 186170). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
- -
not specified Uncertain:1
Variant summary: CHEK2 c.910A>G (p.Met304Val) results in a conservative amino acid change located in the Protein kinase domain (IPR000719) of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 3.6e-05 in 250794 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.910A>G has been reported in the literature in individuals affected with Hereditary Breast And Ovarian Cancer Syndrome and/or colorectal cancer (Infante_2024). These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication has been ascertained in the context of this evaluation (PMID: 38061684). ClinVar contains an entry for this variant (Variation ID: 186170). Based on the evidence outlined above, the variant was classified as uncertain significance. -
CHEK2-related disorder Uncertain:1
The CHEK2 c.910A>G variant is predicted to result in the amino acid substitution p.Met304Val. This variant has been reported in breast cancer cohort studies (Supplement, Decker et al. 2017. PubMed ID: 28779002; Table S3, Weitzel et al. 2019. PubMed ID: 31206626). This variant is reported in 0.023% of alleles in individuals of Latino descent in gnomAD (http://gnomad.broadinstitute.org/variant/22-29095924-T-C). It is interpreted as uncertain significance in ClinVar (https://preview.ncbi.nlm.nih.gov/clinvar/variation/186170/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at